dpp 4 inhibitor glp 1 agonist DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits | Military Medical Research DPP-4 inhibitors and GLP-1RAs: cardiovascular

doi: 10.1016/j.peptides.2017.11.023

MLS To view or add a comment, sign in GLP-1 Receptor Agonists and Early Pregnancy: A Step Forward in Real-World Evidence The evolving GLP-1 landscape continues to surprise usnot only with advances in glycemic control, weight management, and cardiovascular outcomes but now with emerging data on early pregnancy exposure

Important considerations before switching GLP-1 therapy The following are important considerations before switching GLP-1 medications: Oral vs

In July 2024, Pfizer announced that based on results from the ongoing pharmacokinetic study (NCT06153758), the company selected its preferred once-daily modified release formulation for danuglipron , an oral glucagon-like peptide-1 (GLP-1) receptor agonist

The program will run between July 1, 2026, and December 31, 2027

Understanding the complex interactions between GLP-1RA medications, risk factors for PDAC, and pancreatic tumorigenesis will require the development of new preclinical models, which will be complementary to longer-term studies in humans